NASH limits anti-tumour surveillance in immunotherapy-treated HCCDominik Pfister(Novo Nordisk (Denmark))NatureMarch 24, 202110.1038/s41586-021-03362-0Cited by 1,219SaveCiteExport RISWatch citationsRelated PapersIntestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling|Journal of Hepatology|2023|92